Corcept Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Corcept Therapeutics Incorporated
CORT Stock  USD 55.31  0.87  1.60%   
Corcept Therapeutics financial statements provide useful quarterly and yearly information to potential Corcept Therapeutics Incorporated investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Corcept Therapeutics financial statements helps investors assess Corcept Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Corcept Therapeutics' valuation are summarized below:
Gross Profit
618.8 M
Profit Margin
0.2256
Market Capitalization
5.8 B
Enterprise Value Revenue
8.6254
Revenue
628.6 M
There are currently one hundred twenty fundamental signals for Corcept Therapeutics Incorporated that can be evaluated and compared over time across rivals. All traders should validate Corcept Therapeutics' prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 3.2 B in 2025. Enterprise Value is likely to gain to about 3.1 B in 2025

Corcept Therapeutics Total Revenue

582.47 Million

Check Corcept Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corcept Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 4.3 M, Selling General Administrative of 193.1 M or Research Development of 222.6 M, as well as many indicators such as Price To Sales Ratio of 7.62, Dividend Yield of 0.0 or PTB Ratio of 6.27. Corcept financial statements analysis is a perfect complement when working with Corcept Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Corcept Therapeutics Correlation against competitors.

Corcept Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets750.5 M714.7 M310.5 M
Slightly volatile
Total Current Liabilities126.2 M120.2 M40.4 M
Slightly volatile
Accounts Payable21 M20 M8 M
Slightly volatile
Cash116.6 M155.9 M161.8 M
Slightly volatile
Other Current Assets50.2 M47.8 M14 M
Slightly volatile
Total Liabilities138.6 M132 M53.4 M
Slightly volatile
Common Stock85.9 K152.9 K107.6 K
Slightly volatile
Property Plant Equipment2.1 M2 M849.2 K
Slightly volatile
Other Assets93.5 M89.1 M43.3 M
Slightly volatile
Common Stock Shares Outstanding83.1 M128.5 M104.3 M
Slightly volatile
Liabilities And Stockholders Equity750.5 M714.7 M312 M
Slightly volatile
Short and Long Term Debt Total165 K173.7 K11.9 M
Slightly volatile
Property Plant And Equipment Net559.2 K362.2 K683.7 K
Slightly volatile
Non Current Assets Total196.7 M187.3 M59.5 M
Slightly volatile
Non Currrent Assets Other17.9 M17 M8.4 M
Slightly volatile
Cash And Short Term Investments444.6 M423.5 M214.2 M
Slightly volatile
Common Stock Total Equity87.7 K146.1 K106.6 K
Slightly volatile
Property Plant And Equipment Gross709.1 K362.2 K863.4 K
Slightly volatile
Total Current Assets553.8 M527.4 M251.7 M
Slightly volatile
Current Deferred Revenue22.3 M21.2 M8.4 M
Slightly volatile
Short Term Debt165 K173.7 K4.1 M
Slightly volatile
Capital Surpluse426.4 M680.1 M424.8 M
Slightly volatile
Net Receivables49.7 M47.3 M19.4 M
Slightly volatile
Long Term Debt Total19.1 M11.3 M17.8 M
Slightly volatile
Short and Long Term Debt14.3 M16.9 M13.2 M
Slightly volatile
Net Invested Capital431.5 M582.7 M318.5 M
Slightly volatile
Net Working Capital313.5 M407.3 M211.1 M
Slightly volatile
Deferred Long Term Asset Charges61.4 M69 M75.3 M
Slightly volatile
Other Liabilities11 M10.5 M2.7 M
Slightly volatile
Capital Stock137.5 K152.9 K123.5 K
Slightly volatile
Non Current Liabilities Other349.7 K368.1 K455.2 K
Pretty Stable
Capital Lease Obligations129.1 K135.9 K2.5 M
Slightly volatile

Corcept Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative193.1 M165.8 M84.7 M
Slightly volatile
Research Development222.6 M212 M81.1 M
Slightly volatile
Other Operating Expenses452.9 M431.4 M174.3 M
Slightly volatile
Total Operating Expenses445.1 M423.9 M170.8 M
Slightly volatile
Depreciation And Amortization770.3 K1.2 M894.1 K
Slightly volatile
Selling And Marketing Expenses3.6 B4 B4.4 B
Slightly volatile
Interest Income20.9 M19.9 M5.8 M
Slightly volatile
Reconciled Depreciation2.1 M2.7 M1.2 M
Slightly volatile

Corcept Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditures118.8 K125.1 K314 K
Slightly volatile
End Period Cash Flow163.7 M155.9 M68.8 M
Slightly volatile
Begin Period Cash Flow39.3 M76.3 M49.1 M
Slightly volatile
Depreciation2.9 M2.7 M1.2 M
Slightly volatile
Stock Based Compensation79.3 M44 M125 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio7.628.0219.1045
Slightly volatile
Days Sales Outstanding43.5335.7842.3211
Slightly volatile
Stock Based Compensation To Revenue0.110.120.4524
Slightly volatile
Capex To Depreciation0.06430.06775.6566
Slightly volatile
EV To Sales7.317.712.9909
Slightly volatile
Inventory Turnover0.790.750.4493
Slightly volatile
Days Of Inventory On Hand4765011.4 K
Slightly volatile
Payables Turnover0.420.340.4485
Slightly volatile
Sales General And Administrative To Revenue192182189
Slightly volatile
Research And Ddevelopement To Revenue0.420.445.3557
Slightly volatile
Capex To Revenue3.0E-43.0E-40.2875
Slightly volatile
Cash Per Share3.363.22.6757
Slightly volatile
Days Payables Outstanding1.1 K1.1 K3.8 K
Slightly volatile
Current Ratio3.753.9511.5969
Pretty Stable
Receivables Turnover8.2810.569.6834
Slightly volatile
Graham Number10.049.566.0706
Slightly volatile
Capex Per Share0.00150.00150.355
Slightly volatile
Revenue Per Share4.44.191.9363
Slightly volatile
Interest Debt Per Share0.00120.00130.052
Slightly volatile
Debt To Assets2.0E-42.0E-40.0623
Slightly volatile
Operating Cycle5105361.5 K
Slightly volatile
Days Of Payables Outstanding1.1 K1.1 K3.8 K
Slightly volatile
Ebt Per Ebit1.271.3461.5659
Slightly volatile
Long Term Debt To Capitalization1.11.040.9386
Slightly volatile
Total Debt To Capitalization3.0E-43.0E-40.1658
Slightly volatile
Quick Ratio3.693.8811.1833
Pretty Stable
Net Income Per E B T1.030.981.5115
Slightly volatile
Cash Ratio1.111.179.9094
Pretty Stable
Days Of Inventory Outstanding4765011.4 K
Slightly volatile
Days Of Sales Outstanding43.5335.7842.3211
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.661.151.5219
Slightly volatile
Fixed Asset Turnover1.4 K1.4 K467
Slightly volatile
Debt Ratio2.0E-42.0E-40.0623
Slightly volatile
Price Sales Ratio7.628.0219.1045
Slightly volatile
Asset Turnover0.420.70.5948
Slightly volatile
Gross Profit Margin0.780.890.9606
Slightly volatile

Corcept Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.2 B3 B2 B
Slightly volatile
Enterprise Value3.1 B2.9 B1.9 B
Slightly volatile

Corcept Fundamental Market Drivers

Forward Price Earnings30.3951
Cash And Short Term Investments368.2 M

Corcept Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Corcept Therapeutics Financial Statements

Corcept Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Corcept Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Corcept Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Corcept Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue21.2 M22.3 M
Total Revenue554.7 M582.5 M
Cost Of Revenue5.8 M5.7 M
Stock Based Compensation To Revenue 0.12  0.11 
Sales General And Administrative To Revenue 182.39  191.51 
Research And Ddevelopement To Revenue 0.44  0.42 
Revenue Per Share 4.19  4.40 
Ebit Per Revenue 0.20  0.21 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Corcept Stock Analysis

When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY